-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In a previous randomized phase II study (NVALT-10), the study found that combined chemotherapy + erlotinib in the treatment of patients with relapsed advanced non-squamous non-small cell lung cancer (NSQ- NSCLC ) improved compared with erlotinib monotherapy Overall survival (OS)
In a previous randomized phase II study (NVALT-10), the study found that combined chemotherapy + erlotinib in the treatment of patients with relapsed advanced non-squamous non-small cell lung cancer (NSQ- NSCLC ) improved compared with erlotinib monotherapy Overall survival (OS)
The NVALT-18 study is a prospective, multicenter, randomized, open phase III clinical study.
The NVALT-18 study is a prospective, multicenter, randomized, open phase III clinical study.
From October 2016 to April 2018, a total of 45 patients were randomly assigned to receive treatment in the control group (N = 23) or the experimental group (N = 22).
The PFS of the docetaxel single-agent group and the combination group were 4.
PFS and OS of the two groups
The objective response rates of the docetaxel single-agent group and the combination group were 13% (N = 3) and 9% (N = 2), respectively
The objective response rates of the docetaxel single-agent group and the combination group were 13% (N = 3) and 9% (N = 2), respectively
Six patients (26%) in the single-agent group experienced CTCAE grade 3 toxicity, while 17 patients (77%) in the combination group (p = 0.
Adverse reactions
In summary, the study shows that the addition of erlotinib does not improve the prognosis of patients, but has adverse effects, and strongly opposes further exploration of this combination in clinical practice
In summary, the study shows that the addition of erlotinib does not improve the prognosis of patients, but has adverse effects, and strongly opposes further exploration of this combination in clinical practice
Original source:
Steendam CMJ, Peric R, van Walree NC, et al.
Steendam CMJ, Peric R, van Walree NC, et al.
Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma.
Lung Cancer.
2021 Aug 4;160:44-49 .
doi: 10.
1016/j.
lungcan.
2021.
08.
002.
Epub ahead of print.
PMID: 34403911.
Leave a message here
